Indian Journal of Pathology and Oncology 2024;11(2):100–107

Content available at: https://www.ipinnovative.com/open-access-journals

Indian Journal of Pathology and Oncology

Journal homepage: www.ijpo.co.in

Review Article

Comprehensive overview: Car T cell therapy

Bodhimala Nagrale[1]*, Jagruti Koshti[1], Ashwini Chavan[1], Hemant Raut[1], Amit Kakad[1]

[1]*MET's Institute of D Pharmacy, Nashik, Maharashtra, India*

ARTICLE INFO

Article history:
Received 03-05-2024
Accepted 07-06-2024
Available online 09-07-2024

Keywords:
Blood malignancies
Chimeric antigen receptor (CAR)- T cell
Immunotherapy
Tumour cell

ABSTRACT

CAR T cell therapy is now-a-days employed in treating various varieties of cancer like that Blood malignancies, solid tumour, peptic cancer etc. Chimeric antigen receptor are created by taking patient T cells and reprogramming them in a lab to develop a protein or surface that binds to and recognizes particular antigens or protein molecules found on the outer layer of cancer cells. In CAR there are four basic parts named as 1) an antigen-binding domain found outside of the cell, 2) a hinge area, 3) A domain across membranes, and 4) any number of signaling regions within cells. CARs are modular synthetic receptors. There are three generations of CAR i.e. 1) 1st generation CAR 2) 2nd generation CAR 3) 3rd generation CAR. CAR T cell therapy is also used in lymphoma, myeloma, in solid tumour such as breast cancer. Recently ROR-1 CAR T cell is used which support death of tumour cell.

1. Introduction

Chimeric antigen receptor -T cell treatment has yielded extremely lasting and successful clinical results, making it a novel approach.[1] Following two or more rounds of systemic therapy, two products of chimeric antigen receptor (CAR) T-cells that target CD19 are currently licensed with the purpose of treating relapsed huge lymphoma of the B cells in the US furthermore Europe.[2] The form of therapy may be referred to as immunotherapy, gene therapy, or cancer therapy when T lymphocytes are genetically modified to express these synthetic receptors in order to target cancer cells.[3] Complete remission rate (CRR) of B cell acute lymphoblastic leukaemia (B-ALL) handled with CD19-targeted CAR-T (CAR-T-19) cells may exceed 90%.[4,5] T-cell antigen specificity determines how well cancer immunotherapy techniques work. It is possible to genetically alter T-cells that to target antigens that are overexpressed in tumors, which will increase their specificity. Chimeric antigen receptors, which increase antigen affinity, or modified TCRs (also known as TCR treatments) can be expressed by the patient's own T cells. By overcoming the basic drawbacks of both peripheral and central tolerance, these strategies produce T-cells that are more effective at destroying malignancies without the need for the patient to undergo de novo T-cell activation.[6] For over 20 years, researchers have been investigating the engineering of T cells to express chimeric antigen receptors that target tumor antigens.[6] Liposomas of B cells and acute lymphoblastic leukemia are two hematological malignancies for which CAR-T therapy has completely changed treatment. Currently, the FDA has approved two CAR-T cell-based therapies: tisagenlecleucel and axicabtagene ciloleuce.[7,8]

* *Corresponding author*.
E-mail address: amitkakad12@gmail.com (B. Nagrale).

https://doi.org/10.18231/j.ijpo.2024.025

2. CAR T Cell Therapy

A newly developed immunotherapy to a variety and of tumours is referred to as CAR.[9,10] Leukapheresis, or the isolation of a patient's peripheral blood, is the first stage in this treatment. Blood is extracted from patients using a process known as apheresis, and the constituent parts are subsequently genetically modified before being reinjected into the patient. Blood banks currently employ apheresis to gather platelets and other blood components for the treatment of various illnesses, such as renal and hematologic problems. For those who are healthy and patients, it is therefore considered a safe technique.[11]

3. CAR Design

The four basic parts of CARs are an expressed target antigen-binding domain, a hinge area, a transmembrane domain, and one or more intracellular signaling domains. CARs are modular synthetic receptors. The CAR's extracellular domain is made up of a spacer and an antigen binding moiety. These antigen-binding molecules may be natural ligands that bind to their corresponding receptors, a human Fab fragment chosen from libraries of phage screens, or a scFv (single-chain fragment variable) produced from antibodies.[12]



Figure 1: Structure of CAR

3.1. Antigen binding domain

The part from the CAR that gives selectivity of target antigen is called the antigen binding domain. Traditionally, single-chain variable fragments (scFv) are formed by joining the flexible linker between the variable heavy (VH) and light (VL) chains of monoclonal antibodies to generate the antigen-binding domains. Traditionally, External surface cancer antigens are the target of the scFvs in CARs, which causes major histocompatibility complex (MHC)-independent T cell activation. However, it has been reported that MHC-dependent, T cell receptor (TCR)-mimic CARs can identify intracellular tumor-related antigens.[13] Going beyond simply locating and attaching to the target area, a number of scFv properties affect CAR working. For example, the CAR's affinity and selectivity for its target epitope are influenced through the mechanism of conversation between both the VH and VL chains and their respective positions of the complementarity-determining domains.[14] Since affinity essentially controls CAR function, affinity is an important antigen-binding domain parameter. The CAR's antigen binding affinity must be high enough to identify antigens on tumor cells, initiate CAR signaling, and activate T cells, but not so high as to cause activation-induced T cell division and cause toxicities.[15,16] Although attachment is undoubtedly among the most significant elements that exacerbate the situation, studies have shown that even scFvs with comparable attraction may have differing effects on CAR-T cell activity. Therefore, other criteria including the position of epitopes and target antigen quantity, and avoiding scFvs linked to ligand-independent tonic signaling has to be taken into account to get better binding of the CAR to the antigen it is pursuing.

3.2. Hinge region

The hinge or spacer region is the extracellular structural area from which the binding units extend from the transmembrane domain. The hinge adds length to enable the antigen-binding domain to reach the targeted epitope and serves as a flexible means of overcoming steric hindrance. Crucially, it seems that the hinge that is chosen influences CAR functionality since variations in the hinge region's length and makeup can have an effect on signaling, CAR creation, flexibility, epitope recognition, and the strength of activation outputs.[17,18] Apart from these effects, it's been suggested that the distance between two points plays a vital role in ensuring sufficient spacing within cells to facilitate the development of autoimmune synapses.[20] Degree of Structural impediment on the intended cell determine, in theory, the "optimal" spacer length. Long spacers offer greater adaptability and enable more efficient entry to complex glycosylated antigens or membrane-proximal epitopes, whereas little hinges are better when attaching membrane-distal epitopes.[17,19] In actuality, but still, the appropriate spacing distance needs to be customized for every unique antigen-binding domain pair and is frequently established empirically. The literature is replete with examples of short spacer CARs (carcinoembryonic antigen (CEA) and CD19).[20] The membrane-proximal epitopes of ROR1, orphan receptor tyrosine kinase-like,), as alright as extended spacer CARs (mucin 1 (MUC1)).[19] Hinges sections that are most frequently used are taken from amino acid arrangement found in CD8, CD28, IgG1, or IgG4. However, because IgG-originated spacers can interact with Fcγ receptors, they can promote depletion of CAR-T cells and hence reduced persistence within vivo.[21,22] The spacer zone can be further engineered based on structural or functional considerations, or an alternative spacer region can be chosen to prevent these impacts.

3.3. Transmembrane domain

The domain of transmembranes is most likely the least well defined area of all the CAR components. Although data implies that the domain of transmembrane may potentially be important for CAR-T cell work, its primary binding the CAR to the T cell membrane is its function. According to research, the CAR transmembrane domains specifically impact the stability and degree of CAR expression. They can also be involved in signaling or development of synapse and divide with internal signaling chemical.[23–25] The majority of transmembrane domains, such as CD3ζ, CD4, CD8α, or CD28, are derived from naturally occurring proteins. Due of the transmembrane domain's frequent changes in response to the demands of the intracellular signaling domains or the extracellular spacer region, the impact of different transmembranes on CAR work have not been thoroughly investigated. Interestingly, as the CD3ζ domain of transmembrane enables CAR diminishing and integration into internal TCRs, it may aid in CAR-mediated T cell initiation.[23] The benefits of the CD3ζ transmembrane domain are greater than those of CARs with the CD28 transmembrane domain, although CAR stability is reduced as a result.[26] When in contrast to to CARs with these domains derived from CD28, CD8α transmembrane and hinge domains on CAR-T cells release fewer TNF and IFNγ and are less perceptible to activation-induced cell death (AICD). These data suggest that The cytokine production and AICD of CAR-T cells are influenced by the transmembrane domain and hinge region.[30] Overall, research indicates that while CAR expression and stability may be improved by employing the commonly utilized CD8α or CD28 Using the frequently used CD8α or CD28 transmembrane domains may increase stability. transmembrane domains, correct CAR-T cell signaling may be best facilitated by connecting the proximal intracellular domain to the matching transmembrane domain.

3.4. Intracellular signaling domain (s)

Recognising the effects of CAR co-stimulation in order to produce CAR forms with the ideal Endo domain has gotten the most focus in CAR engineering, perhaps. 1^{st} generation CARs with an FcRγ or CD3ζ signaling domain were created in the late 1990s.[27] The overwhelming majority of CARs depend on CD3γ derived immunoreceptor tyrosine-based activation patterns to activate CAR-T cells.[28] It is not possible to elicit effective T cell responses only through the use of these patterns in signaling. These first generation CARs' in vitro stability and durability are lacking.[29] Clinical trials that shown little to no efficacy confirmed these findings.[30,31]

4. Toward blood malignancies: CAR T-Cell therapy

Anti-CD19 CAR T-cells have shown to be remarkably effective in treating R/R (relapsed or refractory) B-cell malignancies, including B-cell non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL), in both young people's and adult individuals. The percentage of complete remissions in these trials ranged from 70 to 94%.[32] Although CAR T cells focusing CD19 have a remarkably high response rate in lymphocytic leukemias, antigen escape, or the disappearance of recognisable CD19 on tumor cells' surface, has also have been found in approximately 10–20% of pediatric Cancer patients having CD19-directed immunotherapy.[33] Therefore, the search for more unique targeted hematology markers is necessary. Concerning a) myelogenous leukemia (MM), which targets CD138 or B-cell maturation antigen (BCMA)[34,35] and b) acute myelogenous leukemia (AML), which targets CD33 and CD123, more clinical trials are being conducted.[36] The FDA, EMA, and other regulatory bodies have acknowledged that the application of CAR T-cells is an innovative treatment strategy. Actually, the first CAR therapy to hit the market was "tisagenlecleucel-T" (Kymriah, Novartis), which is meant for use in young adult and pediatric patients (ages 3 to 25) with R/R ALL. On August 30, 2017, the FDA approved the product, which comes at a price of $475,000. Additionally, the FDA is now reviewing Kymriah's regulatory status for R/R B-cell ALL and DLBCL in Europe, as well as for adults with R/R diffuse large B-cell lymphoma (DLBCL), an aggressive subtype of NHL. Additionally, Kymriah is being evaluated for FL (Florida Law), 2^{nd} line DLBCL, CLL, and MM. On October 18, 2017, the FDA approved "axicabtagene ciloleucel" (Yescarta, Kite Phama), a second T-cell therapy that carries a $373,000 price tag, for the patient care with R/R aggressive B-cell NHL who are not eligible for autonomous stem cell transplantation (after at least two lines of systemic therapy). Regretfully, the cost of a single treatment using these medicines is now rather high. Yet, it is expected that over the next few years, the cost would drop drastically as the production scale rises and businesses lead the way in the creation of artificial or commercially available CAR T-cell treatment (that doesn't need a customized production technique). Furthermore, the cost of CAR T-cell therapies would not be too high given that a single therapy can have long-lasting effects in contrast to other therapies, such as antibodies, which need for prolonged and expensive care. With the first treatments now available, the door is now open for additional and better, quicker, and less expensive options to appear soon.[37]

5. CAR T-Cell Therapy towards Solid Tumors

Focusing solid tumors presents a greater difficulty than focusing hematological malignancies; CAR T-cells must overcome numerous obstacles. Tumor cells can cease expressing antigens that T-cells are targeting or lose the mechanisms that present them due to their genetic instability. Furthermore, the histopathological features of the tumor, insufficient "trafficking" of CAR T-cells to growth sites, the local strong suppressor of immunity micro environment, tumor variability, and lack of specific antigens have all contributed to the little success of adoptive CAR T-cell therapy for solid growth thus far.[38] Using early in vivo models of B-cell cancer, the significance of co-stimulation in CD-19-focused CAR-T cell persistence was shown.[39] By including a domain of co-stimulatory area, IL-2 manufacturing and increase in number upon repeated antigen uncertainty were enhanced. 2^{nd} generation CARs were created with one co-stimulatory domain in order with the CD3ζ intracellular signaling domain once it was realized how crucial co-stimulation is for long-lasting CAR-T cell treatment.[40,41] Both 4-1BB (CD137) and CD28, the two most popular co-stimulatory domains that have FDA approval, are linked to significant patient response rates. Upon differentiating into effector memory T cells, CARs with CD28 domains predominantly employ aerobic glycolysis, whereas CARs with the 4-1BB domain differentiate into central memory T cells and show enhanced mitochondrial biogenesis and oxidative metabolism. The co-stimulatory domains' functional and metabolic characteristics are different.[42] In numerous hematological malignancies, such as In multiple myeloma, diffuse large B-cell lymphoma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, 2^{nd} generation CAR-T cells have shown strong therapeutic responses in the clinic. Presently, studies are being conducted to determine the effectiveness of second generation CAR-T cells in solid tumours, such as glioblastoma, progressive sarcoma, liver metastases, mesothelioma, ovarian cancer, and pancreatic cancer.[29] A number of different co-stimulatory domains, including activable T cell co-stimulator (ICOS)[43] CD27,[44] MYD88 and CD40[45] and OX40 (CD134)[46] have shown prior to clinical efficacy; nevertheless, further clinical research is required. 3^{rd} generation CARs, which combine two costimulatory domains in series with CD3ζ, are thought to be produced when co-stimulation through a single domain results in partial activation.[47] Results from prior to clinical research on third-generation CARs have been inconsistent. More specifically, compared to 2^{nd} generation CARs, lung metastasis revealed an improved in vivo anti-tumor reply and increased cytokine production in lymphoma when CARs containing CD28 and 4-1BB signaling were incorporated.[48] 3^{rd} generation CARs did not demonstrate any in vivo therapeutic effects in leukemia or pancreatic cancer models, and they did not outperform 2^{nd} generation CARs in either type.[49,50]

6. Safety Considerations for CAR Therapy

Although the utilisation of CAR T cells has demonstrated remarkable anticancer responses, there are still a number of safety issues about potential adverse effects. Different toxicities are seen a limited days or weeks after CAR T-cell blending, and some can be extremely dangerous.[51,52] The major frequent brief-term side impact of CAR T cell therapy is CRS, which typically occurs together with neurotoxicity. Following CD19 CAR-T cell therapy, CRS has been noticed in 54-91% of individual, with 8.3–43% of individuals experiencing extreme CRS.[53] During the R/R B-ALL phase II trial, patients who took "tisagenlecleucel" were shown to have extreme CRS in 47% of cases and neurotoxicity in 15% of cases.[54] During the key trial for aggressive B-NHL, patients who got "axicabtagene ciloleucel" reported severe CRS and neurotoxicity in percentages of 13% and 28%, respectively.[55] Severe dyspnoea, which often appears one or two hours after the initial infusion and is frequently accompanied by bronchospasm, hypoxia, fever, shivering, hives, coagulopathy, and capillary leak, is the hallmark of CRS. Activation of CAR T-cells follows detection of CD19+ tumor or normal B-cells; this leads to the TNF-α, IL-6, and IFN-γ proinflammatory cytokine release by the T-cells, lysis of target cells, and other effects that can be linked to neurotoxicity and clinical signs of CRS. Certain tumor lysis syndrome symptoms, including hyperuricemia, hyperkalaemia, hypocalcaemia, hyperphosphatemia, acute renal failure, increased LDH, acute respiratory failure, and additionally mortality, may also be linked to CRS. Chest X-rays can show interstitial pulmonary infiltration or edema in conjunction with acute respiratory failure. Though the processes underlying these symptoms are unknown, they appear to be temporary and reversible without causing long-term consequences.[56]

7. Methods to Improve CAR-T Cell Safety in Solid Tumors

Beyond hematological malignancies, extreme treatment-related toxicities mostly caused by the on-target/off-tumor identification represent one more barrier to CAR-T cell therapy.[57] For this new technology, overcoming the toxicity is critical and has emerged as a center for study. There are various approaches to improving the security of CAR-T cell treatment for solid tumours.

8. Application of CAR T Cell

1. When Eshhar and his associates created the 1^{st} functional CAR T-cells for cancer management in 1989, CAR technology was born (Gross, Waks, & Eshhar, Citation 1989). In current years, CAR T-

Table 1: Strategies for enhancing safety of car-t cell therapy

Methodology			Stage	Ref.
Improving selectivity of CAR	Choosing a less dangerous antigen	Growth-specific antigen	Clinical trail	58
		Aberrantly glycosylated antigen	Preclinical research	59
		TCR-like CAR	Preclinical research	60
	Combinatorial antigen targeting	Supplementary signaling	Preclinical research	61,62
		SynNotch/CAR circulation	Preclinical research	63
		iCAR	Preclinical research	16
	Turning sensitivity of scFv	Turning the gratitude	Preclinical research	15,64
	Masked CAR		Preclinical research	65
Control CAR-T cell activity	Restricting CAR expression	Transient mRNA CAR	Clinical trail	66,67
	Switchable CAR-T cell	Dimerizing small molecules	Preclinical research	68,69
		Tumor targeting antibody	Preclinical research	70–72
	Suicide gene	iCasp9	Clinical trail	73
		Antibody-mediated depletion	Clinical trail	27,74

cell therapy has revolutionized the way that cancer is treated.

2. The possibly successful treatment for B-cell cancers, often known as blood malignancies, is CAR T-cell therapy.
3. Clinical trials against solid tumours, such as ovarian cancer, neuroblastoma, carcinoma, colorectal cancer, glioblastoma, sarcoma, and so on, have also been carried out employing CAR T-cells.[75]
4. One of the main issues restricting the use of CAR-T cell therapy is toxicity. Six categories are used to categorize common toxicities: neurotoxicity, genotoxicity, immunogenicity, off-target toxicity, on-target on-tumor toxicity, and on-target/off-tumor toxicity.[76]
5. The growth of CAR-T cell therapy for the management of solid tumours, such as breast cancer, is encouraged by its effective use in hematologic malignancies.
6. Recently, the use of ROR1-CAR-T cells demonstrated cytolytic activity and cytokine release that support tumor death in 3D micro physiologic tumor models of TNBC.[77]
7. In both chronic lymphocytic leukemia and acute lymphoblastic leukemia, CAR-T cells is used.
8. CAR-T cell therapy in lymphoma
9. CAR-T cell in multiple myeloma

9. List of Abbreviations

TNF: Tumor necrosis factor; ALL: Acute lymphocytic leukemia; AML: Acute myelogenous leukemia; BCMA: B-cell maturation antigen; CAR: Chimeric antigen receptor; CLL: Chronic lymphocytic leukemia; CRS: Cytokine release syndrome; FL: Florida law; iCAR: Inhibitory chimeric antigen receptor; iCasp9: Inducible caspase 9; IL: Interleukin; MM: Multiple myeloma; NHL: Non-hodgkin lymphoma; TNBC: Triple negative breast cancer; TCR: T cell receptor; ROR 1: Receptor tyrosine kinase-like orphan receptor 1; ScFv: Aingle-chain fragment variable; SynNotch: Synthetic notch receptor; DLBCL: Diffuse large B-cell lymphoma.

10. Discussion

The provided overview delves into the intricate landscape of CAR T cell therapy, shedding light on its significance, mechanisms, applications, and challenges. Here's a discussion focusing on key points:

1. Therapeutic potential: CAR T cell therapy represents a paradigm change in cancer treatment, offering a highly targeted approach to combatting cancer. By using the body's immune system, particular T cells, and genetically engineering them to recognize and attack cancer cells, CAR T cell therapy holds immense promise in achieving durable remissions, particularly in blood cancer like B-cell lymphoma and acute lymphoblastic leukemia.[75,76]
2. Design complexity: The overview elucidates the intricate design of CARs, emphasizing the importance of each component - from the antigen-binding domain to the intracellular signaling domains. This modular design allows for customization and optimization to enhance efficacy and specificity while minimizing off-target effects.
3. Challenges in solid growth: While CAR T cell therapy has demonstrated amazing success in blood cancer, its application in solid growth poses significant challenges. These challenges include

tumor heterogeneity, antigen loss, immunosuppressive microenvironments, and limited trafficking of CAR T cells to growth sites. Overcoming these obstacles remains a focal point of ongoing research efforts.

4. Safety considerations: Despite its therapeutic potential, CAR T cell therapy is not without risks. Cytokine release syndrome (CRS) and toxicity of neuron are notable adverse events related with CAR T cell blending. Strategies to mitigate these risks include selecting safer antigens, controlling CAR-T cell activity, and incorporating suicide genes for cell elimination if necessary.[27,75,77]
5. Future directions: The overview highlights ongoing efforts to enhance the safety and efficacy of CAR T cell therapy, particularly in the context of solid growth. Strategies such as enhancing CAR selectivity, controlling CAR-T cell activity, and exploring novel targets hold promise in expanding the applicability of CAR T cell therapy beyond hematologic malignancies.

In conclusion, CAR T cell therapy represents a groundbreaking approach in cancer treatment, with the potential to revolutionize oncology. While challenges remain, continued research and innovation hold the key to unlocking the full therapeutic potential of this transformative therapy.

11. Conclusion

CAR T cell therapy, a form of therapy of immune system, is a assurance treatment for various cancers including blood malignancies and solid tumors. Chimeric antigen receptors are engineered to recognize specific antigens on cancer cells, enhancing T cell targeting. CAR-T cell therapy has shown amazing success in treating relapsed or condensable large B-cell lymphoma and acute lymphoblastic leukemia (ALL). The therapy involves genetically changing individual T cells to describe synthetic receptors targeting cancer cells. The process involves isolating patient T cells, genetically changing them in a lab, and reintroducing them into the patient. CARs consist of four main parts: antigen-binding domain, hinge region, transmembrane domain, and intracellular signaling domains. Each part of the CAR plays a vital role in its function. The antigen-binding domain provides target particularity, the hinge region allows acceptability, the transmembrane domain anchors the CAR to the T cell membrane, and the intracellular signaling domains activate T cells. CAR T cells targeting CD19 have displayed significant effectiveness in treating B-cell cancer. However, antigen escape poses challenges, necessitating the exploration of alternative targets such as BCMA for multiple myeloma and CD33/CD123 for acute myelogenous leukemia. Targeting solid growth presents challenges including antigen loss and immunomodulator microenvironments. 2^{nd} generation CARs with co-stimulatory domains have shown promise in hematological malignancies, but their efficacy in solid growth is still under investigation. While CAR T cells demonstrate anticancer responses, safety concerns include cytokine release syndrome (CRS) and neurotoxicity. Strategies to enhance safety include selecting safer antigens, controlling CAR-T cell activity, and using suicide genes for cell elimination if necessary. Various strategies are being explored to improve the safety of CAR-T cell therapy for solid growth, including enhancing CAR selectivity and controlling CAR-T cell activity. CAR T cell therapy has revolutionized cancer treatment, showing promise in hematologic malignancies and ongoing clinical trials for solid growth. Challenges such as toxicity and antigen escape are being addressed to expand its application. In short, CAR T cell therapy has emerged as a powerful tool in cancer management, particularly for blood cancer. While challenges remain, ongoing research aims to enhance its efficacy and safety, paving the way for broader applications in oncology.

12. Source of Funding

None.

13. Conflict of Interest

None.

References

1. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. *Science*. 2018;359(6382):1361–5.
2. Neelapu SS. Managing the toxicities of CAR T-cell therapy. *Hematol Oncol*. 2019;37(Suppl 1):48–52.
3. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: Harnessing the T cell response. *Nat Rev Immunol*. 2012;12(4):269–81.
4. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med*. 2014;371(16):1507–17.
5. Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo Z, et al. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. *Oncotarget*. 2015;6(32):33961–71.
6. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. *Cell*. 1991;64(5):891–901.
7. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A*. 1993;90(2):720–4.
8. Ahmad A, Uddin S, Steinhoff M. Car-t cell therapies: An overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large b-cell lymphomas. *Int J Mol Sci*. 2020;21(11):3906.
9. Miliotou AN, Papadopoulou LC. CAR T-cell therapy: A new era in cancer immunotherapy. *Curr Pharm Biotechnol*. 2018;19(1):5–18.
10. Mirzaei HR, Jamali A, Jafarzadeh L, Masoumi E, Alishah K, Mehrjardi F, et al. Construction and functional characterization

of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells. *J Cell Physiol*. 2019;234(6):9207–15.
11. Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. *Curr Opin Biotechnol*. 2018;53:164–81.
12. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. *Cancer Discov*. 2013;3(4):388–98.
13. Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. *Sci Rep*. 2014;4:1–8.
14. Chailyan A, Marcatili P, Tramontano A. The association of heavy and light chain variable domains in antibodies: implications for antigen specificity. *FEBS J*. 2011;278(16):2858–66.
15. Liu X. Affinity-Tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. *Cancer Res*. 2015;75:3596–3607.
16. Caruso HG. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. *Cancer Res*. 2015;75:3505–3518.
17. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. *Cancer Immunol Res*. 2015;3(2):125–35.
18. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumours. *Curr Opin Immunol*. 2015;33:9–15.
19. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. *J Immunol*. 2008;180(7):4901–9.
20. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. *J Immunother*. 2005;28(3):203–11.
21. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. *Gene Ther*. 2010;17(10):1206–13.
22. Almasbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. *Gene Ther*. 2015;22(5):391–403.
23. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. *J Immunol*. 2010;184(12):6938–49.
24. Guedan S, Posey AD, Shaw C, Wing A, Da T, Patel PR, et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI Insight*. 2018;3(1):e96976.
25. Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. *J Immunol*. 2012;189(5):2290–9.
26. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. *Immunol Rev*. 2014;257(1):107–26.
27. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci U S A*. 1989;86(24):10024–8.
28. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. *Nat Rev Clin Oncol*. 2020;17(3):147–167.
29. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. *J Exp Med*. 1995;181(5):1653–9.
30. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. *Blood*. 2008;112(6):2261–71.
31. Hege KM. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. *J Immunother Cancer*. 2017;5:22–22.
32. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. *Biomark Res*. 2017;5:22.
33. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. *Cancer Discov*. 2015;5(12):1282–95.
34. Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T cell therapies for multiple myeloma. *Blood*. 2017;130(24):2594–2602.
35. Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ. CAR T cell therapy for multiple myeloma: where are we now and where are we headed? *Leuk Lymphoma*. 2018;59(9):2056–67.
36. Im A, Pavletic SZ. Immunotherapy in hematologic malignancies: Past, present, and future. *J Hematol Oncol*. 2017;10(1):94.
37. Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. *Nat Rev Drug Discov*. 2018;17(3):161–2.
38. Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. *Semin Immunol*. 2016;28(1):64–72.
39. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumours by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. *Nat Med*. 2003;9(3):279–86.
40. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. *Nat Biotechnol*. 2002;20:70–5.
41. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia*. 2004;18(4):676–84.
42. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. *Immunity*. 2016;44(2):380–90.
43. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. *Blood*. 2014;124(7):1070–80.
44. Song DG, Powell DJ. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. *Oncoimmunology*. 2012;1(4):547–9.
45. Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. *Cancer Discov*. 2017;7(11):1306–19.
46. Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. *Oncoimmunology*. 2012;1(4):458–66.
47. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. *Mol Ther*. 2005;12(5):933–41.
48. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. *Mol Ther*. 2010;18:413–420.
49. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. *Hum Gene Ther*. 2014;25(12):1003–12.
50. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Mol Ther*. 2009;17(8):1453–

64.
51. Abken H. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells. *Hum Gene Ther*. 2017;28(11):1047–60.
52. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: Recognition and management. *Blood*. 2016;127(26):3321–30.
53. Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood*. 2017;130(21):2295–2306.
54. Buechner J, Grupp SA, Maude SL, Boyer M, Bittencourt H, Laetsch TW, et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Update to the interim analysis. *Clin Lymph Myeloma Leuk*. 2017;17:263–4.
55. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377(26):2531–44.
56. Wang Z, Liu Q. Clinical pharmacological considerations on CAR-T cell therapy for cancer. *J Pharmacol Clin Res*. 2017;3(4):1–4.
57. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther*. 2010;18(4):843–51.
58. O'rourke DM, Nasrallah M, Morrissette JJ, Melenhorst JJ, Lacey SF, Mansfield K, et al. Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma. *ASCO Meeting Abstracts*. 2016;34(15_suppl):2067.
59. Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. *Immunity*. 2016;44(6):1444–54.
60. Wilkie S, Schalkwyk MCV, Hobbs S, Davies DM, Stegen S, Pereira ACP, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. *J Clin Immunol*. 2012;32(5):1059–70.
61. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. *Nat Biotechnol*. 2013;31(1):71–5.
62. Roybal KT, Rupp LJ, Morsut L, Walker WJ, Mcnally KA, Park JS, et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. *Cell*. 2016;164(4):770–9.
63. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. *Sci Transl Med*. 2013;5(215):215–72.
64. Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EEM, Liang TW, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. *Sci Transl Med*. 2013;5(207):207–144.
65. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunol Res*. 2014;2(2):112–20.
66. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunol Res*. 2013;1(1):26–31.
67. Juillerat A, Marechal A, Filhol JM, Valton J, Duclert A, Poirot L, et al. Design of chimeric antigen receptors with integrated controllable transient functions. *Sci Rep*. 2016;6:18950.
68. Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. *Science*. 2015;350(6258):aab4077.
69. Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, et al. Design of switchable chimeric antigen receptor T cells targeting breast cancer. *Angew Chem Int Ed Engl*. 2016;55(26):7520–4.
70. Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. *Proc Natl Acad Sci*. 2016;113(4):450–8.
71. Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. *Proc Natl Acad Sci U S A*. 2016;113(4):459–68.
72. Stasi A, Tey SK, Dotti SK, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. *N Engl J Med*. 2011;365(18):1673–83.
73. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. *J Clin Invest*. 2016;126(6):2123–38.
74. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. *Sci Transl Med*. 2016;8(355):355–116.
75. Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. *J Immunol Res*. 2018;2018:2386187. doi:10.1155/2018/2386187.
76. Yang YH, Liu JW, Lu C, Wei JF, Car-T. Cell Therapy for Breast Cancer: From Basic Research to Clinical Application. *Int J Biol Sci*. 2022;18(6):2609–26.
77. Wallstabe L, Gottlich C, Nelke LC, Kuhnemundt J, Schwarz T, Nerreter T. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. *JCI Insight*. 2019;.

Author biography

Bodhimala Nagrale, Student

Jagruti Koshti, Student

Ashwini Chavan, Student

Hemant Raut, Assistant Professor

Amit Kakad, Assistant Professor https://orcid.org/0000-0001-7419-2496

Cite this article: Nagrale B, Koshti J, Chavan A, Raut H, Kakad A. Comprehensive overview: Car T cell therapy. *Indian J Pathol Oncol* 2024;11(2):100-107.